Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, will present at the 13th Annual Ovarcoming Cancer Conference on September 18, 2025. Dr. Wenham, who serves as the principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will discuss advancements in ovarian cancer research and therapies.
The conference, held both virtually and in-person at the Briar Club in Houston, Texas, brings together survivors, caregivers, and medical professionals to discuss important developments in ovarian cancer treatment.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che il dott. Robert Wenham, responsabile del Programma di Oncologia Ginecologica presso il Moffitt Cancer Center, presenter脿 al 13掳 Congresso Annuale Ovarcoming Cancer il 18 settembre 2025. Il dott. Wenham, che 猫 il ricercatore principale dello studio clinico di Fase 1 in corso di Anixa sulla terapia CAR-T per il cancro ovarico, discuter脿 dei progressi nella ricerca e nelle terapie per il cancro ovarico.
La conferenza, che si terr脿 sia in modalit脿 virtuale che in presenza presso il Briar Club di Houston, Texas, riunisce sopravvissuti, caregiver e professionisti medici per discutere importanti sviluppi nel trattamento del cancro ovarico.
Anixa Biosciences (NASDAQ: ANIX) anunci贸 que el Dr. Robert Wenham, presidente del Programa de Oncolog铆a Ginecol贸gica en el Moffitt Cancer Center, presentar谩 en la 13陋 Conferencia Anual Ovarcoming Cancer el 18 de septiembre de 2025. El Dr. Wenham, quien es el investigador principal del ensayo cl铆nico de fase 1 en curso de Anixa sobre la terapia CAR-T para el c谩ncer de ovario, hablar谩 sobre los avances en la investigaci贸n y tratamientos para el c谩ncer de ovario.
La conferencia, que se realizar谩 tanto de forma virtual como presencial en el Briar Club en Houston, Texas, re煤ne a sobrevivientes, cuidadores y profesionales m茅dicos para discutir importantes avances en el tratamiento del c谩ncer de ovario.
Anixa Biosciences (NASDAQ: ANIX)電� Moffitt Cancer Center鞚� 攵�鞚胳晹 頂勲攴鸽灗 毂呾瀯鞛愳澑 Robert Wenham 氚曥偓臧� 2025雲� 9鞗� 18鞚检棎 鞐措Μ電� 鞝�13須� 鞐半 Ovarcoming Cancer 旎嵓霟办姢鞐愳劀 氚滍憸頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. Wenham 氚曥偓電� Anixa鞚� 歆勴枆 欷戩澑 雮滌唽鞎� CAR-T 旃橂 1靸� 鞛勳儊鞁滍棙鞚� 欤检殧 鞐瓣惮鞛愲靹� 雮滌唽鞎� 鞐瓣惮 氚� 旃橂鞚� 歆勳爠鞐� 雽�頃� 雲检潣頃� 鞓堨爼鞛呺媹雼�.
鞚� 旎嵓霟办姢電� 韰嶌偓鞀� 頊挫姢韯挫棎 鞙勳箻頃� Briar Club鞐愳劀 鞓澕鞚戈臣 鞓ろ攧霛检澑鞙茧 霃欖嫓鞐� 臧滌禍霅橂┌, 靸濎〈鞛�, 霃岆磩 鞝滉车鞛�, 鞚橂 鞝勲臧�霌れ澊 氇棳 雮滌唽鞎� 旃橂鞚� 欷戩殧頃� 氚滌爠 靷暛鞚� 雲检潣頃╇媹雼�.
Anixa Biosciences (NASDAQ : ANIX) a annonc茅 que le Dr Robert Wenham, pr茅sident du programme d'oncologie gyn茅cologique au Moffitt Cancer Center, pr茅sentera lors de la 13e conf茅rence annuelle Ovarcoming Cancer le 18 septembre 2025. Le Dr Wenham, qui est l'investigateur principal de l'essai clinique de phase 1 en cours d'Anixa sur la th茅rapie CAR-T pour le cancer de l'ovaire, abordera les avanc茅es dans la recherche et les traitements du cancer de l'ovaire.
La conf茅rence, qui se tiendra 脿 la fois virtuellement et en pr茅sentiel au Briar Club 脿 Houston, Texas, r茅unit des survivants, des aidants et des professionnels de sant茅 pour discuter des d茅veloppements importants dans le traitement du cancer de l'ovaire.
Anixa Biosciences (NASDAQ: ANIX) gab bekannt, dass Dr. Robert Wenham, Vorsitzender des Programms f眉r gyn盲kologische Onkologie am Moffitt Cancer Center, am 13. j盲hrlichen Ovarcoming Cancer Conference am 18. September 2025 teilnehmen wird. Dr. Wenham, der als Hauptpr眉fer der laufenden Phase-1-Studie zur CAR-T-Therapie bei Eierstockkrebs von Anixa fungiert, wird 眉ber Fortschritte in der Forschung und Therapie bei Eierstockkrebs sprechen.
Die Konferenz, die sowohl virtuell als auch pers枚nlich im Briar Club in Houston, Texas, stattfindet, bringt 脺berlebende, Betreuer und medizinische Fachkr盲fte zusammen, um wichtige Entwicklungen in der Behandlung von Eierstockkrebs zu diskutieren.
- None.
- None.
Dr.
Dr.
Ovarcome is an ovarian cancer foundation envisioned to end the scourge of ovarian cancer. The Ovarcoming Cancer Conference brings together survivors, caregivers, and medical professionals to learn from world renowned experts on topics of greatest importance in the ovarian cancer landscape.
For more information about the conference, visit Ovarcoming Cancer Annual Conference 2025 - Ovarcome.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit 聽or follow Anixa on , , and .
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
View original content to download multimedia:
SOURCE Anixa Biosciences, Inc.
FAQ
When is Dr. Robert Wenham presenting at the Ovarcoming Cancer Conference for Anixa Biosciences (ANIX)?
What is Dr. Robert Wenham's role in Anixa Biosciences' (ANIX) ovarian cancer research?
Where will the 13th Annual Ovarcoming Cancer Conference featuring Anixa Biosciences (ANIX) be held?
What type of cancer treatment is Anixa Biosciences (ANIX) developing?
